Peptide Profile

Retatrutide

Triple GIP/GLP-1/Glucagon Agonist

Overview

Composition

Investigational synthetic peptide and first-in-class triple agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors simultaneously

Mechanism of Action

Activates GIP receptors, GLP-1 receptors, and glucagon receptors, combining incretin effects on glucose regulation and appetite with glucagon-linked effects on energy expenditure and lipid metabolism

Primary Effects

Phase 2 trials reported large body-weight reductions, glycemic improvements, lipid-marker changes, and heart-rate effects, but Phase 3 efficacy publications and regulatory review remain pending

Discovery & Background

Developed by Eli Lilly as LY3437943, extending dual incretin-agonist research by adding glucagon receptor activation to test broader metabolic effects

Phase 1 and Phase 2 studies began in the early 2020s. Phase 3 TRIUMPH and TRANSCEND programs continued through 2024-2026 across obesity, type 2 diabetes, and obesity-related complications.

Not FDA-approved as of May 2026; remains investigational pending Phase 3 publications, regulatory submissions, and agency review. Compounded or research-market products lack approved-drug oversight.

Research Overview

Phase 2 trials reported large weight reductions and metabolic-marker changes, while confirmatory Phase 3 evidence is still needed for approved-use framing

01
Phase 2 obesity research reported large mean weight reductions at 48 weeks
02
Phase 2 type 2 diabetes research showed exposure-related improvements in glycemic and weight endpoints
03
HbA1c and glycemic-control changes were reported in type 2 diabetes subgroups
04
Lipid-marker changes included triglycerides, LDL cholesterol, and HDL
05
Blood-pressure and cardiovascular-risk-marker changes require longer outcomes context
06
Body-composition findings should be interpreted alongside nutrition, activity, and lean-mass preservation concerns
07
The glucagon component is intended to affect energy expenditure and hepatic fat oxidation, but it also adds heart-rate considerations
08
Long-term cardiovascular-outcome and post-approval safety data are not yet available
09
Phase 3 records show completed and active trials through 2026, but peer-reviewed Phase 3 efficacy publications are still pending in the reviewed source set

Not FDA-approved; investigational pending Phase 3 publication and regulatory review

Safety Considerations

Monitoring

Body weight and composition
Blood glucose/HbA1c (especially in diabetics)
Lipid panel (triglycerides, HDL, LDL)
Blood pressure
Liver function tests (if targeting NAFLD)
Gastrointestinal tolerance
Heart rate (glucagon can increase HR)

Side Effects

Gastrointestinal (Very Common)

Nausea
Diarrhea or vomiting
Constipation (less common than with pure GLP-1 agonists due to glucagon)

Cardiovascular

Increased heart rate (glucagon effect)—monitor in patients with cardiovascular conditions
Transient blood pressure changes

Metabolic

Potential hypoglycemia (especially if combined with insulin or sulfonylureas)
Lean-mass loss can accompany rapid weight reduction without nutrition and resistance-training support

Rare but Serious (Class Effects)

Pancreatitis (incretin class risk)
Gallbladder issues (cholecystitis, cholelithiasis) with rapid weight loss
Thyroid concerns (GLP-1 class boxed warning for C-cell tumors in rodents—human relevance uncertain)

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Hypersensitivity to retatrutide or components
Caution in severe cardiovascular disease (due to heart rate increases from glucagon)
Pregnancy or breastfeeding (insufficient safety data)

Educational Notice

Retatrutide is an investigational triple-agonist peptide with Phase 2 evidence showing large weight reductions and metabolic effects. It is not FDA-approved as of May 2026, and peer-reviewed Phase 3 efficacy publications, long-term safety data, and cardiovascular outcomes evidence remain pending. Compounded or research-market products lack approved-drug oversight and may vary in quality. Retatrutide's glucagon component introduces unique considerations such as heart-rate changes, so clinical decisions require qualified medical oversight and individualized risk review.

References